Medetalibeyoglu, A. Et Al. 2021. Serum Endocan Levels on Admission Are Associated With Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study. ANGIOLOGY , vol.72, no.2 , 187-193.

Medetalibeyoglu, A., Emet, S., Kose, M., Akpinar, T. S., Senkal, N., Catma, Y., ... Kaytaz, A. M.(2021). Serum Endocan Levels on Admission Are Associated With Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study. ANGIOLOGY , vol.72, no.2, 187-193.

Medetalibeyoglu, Alpay Et Al. "Serum Endocan Levels on Admission Are Associated With Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study," ANGIOLOGY , vol.72, no.2, 187-193, 2021

Medetalibeyoglu, Alpay Et Al. "Serum Endocan Levels on Admission Are Associated With Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study." ANGIOLOGY , vol.72, no.2, pp.187-193, 2021

Medetalibeyoglu, A. Et Al. (2021) . "Serum Endocan Levels on Admission Are Associated With Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study." ANGIOLOGY , vol.72, no.2, pp.187-193.

@article{article, author={Alpay MEDETALİBEYOĞLU Et Al. }, title={Serum Endocan Levels on Admission Are Associated With Worse Clinical Outcomes in COVID-19 Patients: A Pilot Study}, journal={ANGIOLOGY}, year=2021, pages={187-193} }